Is Broach overvalued or undervalued?

As of 17 June 2025, the valuation grade for Broach has moved from risky to attractive, indicating a significant improvement in its financial standing. The company is currently considered undervalued, with a PE ratio of 11.62, an EV to EBIT ratio of 11.55, and a ROCE of 13.19%. In comparison to its peers, Broach's valuation metrics stand out; for instance, Apollo Hospitals has a PE ratio of 69.68 and an EV to EBITDA of 35.02, while Max Healthcare is marked as very expensive with a PE ratio of 104.87.
Despite a recent decline in stock price, with a current price of 19.15 compared to a previous close of 21.50, Broach's attractive valuation suggests it may present a buying opportunity. The company’s PEG ratio is notably low at 0.00, further supporting the notion that it is undervalued relative to its growth prospects. Overall, Broach's financial ratios and peer comparisons reinforce the conclusion that it is an attractive investment at this time.